Molecular Differences Between Left-Sided Colon and Rectal Cancers

Article

This video examines a pair of studies that looked at molecular variances and clinical differences between left-sided colon and rectal cancers.

 

In this video, Mohamed E. Salem, MD, discusses a pair of studies presented at the 2017 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, held January 19–21 in San Francisco.

The first study looked at 1,457 primary colorectal cancers and examined molecular variances (abstract 522) between left-sided colon and rectal tumors, including differences in gene mutation frequency, protein expression, tumor mutational load, and microsatellite instability.

The second study (abstract 675) looked at clinical differences in patients with left-sided colon and rectal cancers and suggests that tumors in the rectum may carry distinct clinical characteristics.

Related Videos
Immunotherapy may be an “elegant” method of managing colorectal cancer, says Gregory Charak, MD.
Administering neoadjuvant therapy to patients with colorectal cancer may help surgical oncologists attain a negative-margin resection.
Increasing screening for younger individuals who are at risk of colorectal cancer may help mitigate the rising early incidence of this disease.
Laparoscopy may reduce the degree of pain or length of hospital stay compared with open surgery for patients with colorectal cancer.
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.